About Us
Research and Development
Established in 1999, we strongly value the importance of nurturing a working culture of innovation.
-
LifeTech Scientific Corporation Announced 2023 Annual Results：International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid DevelopmentLifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries announced the audited consolidated results for the year ended 31 December 2023.2024 / 04 / 02
-
LifeTech Scientific Corporation Announced 2024 Interim Results：International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the “Group”) announced the consolidated results for the six months ended 30 June 2024 (the “Reporting Period”).2024 / 08 / 30
-
LifeTech Scientific Corporation（1302.HK） Announces 2023 Interim ResultsLifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2023 (the “Reporting Period”).2023 / 08 / 30
-
LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results.2023 / 03 / 30
-
FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the USLifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States2022 / 09 / 05
Becoming a globally-recognized, trustworthy and innovative interventional medical device enterprise
